While the development of novel risk factors for cardiovascular risk assessment is necessary to improve risk stratification, proving its clinical value on top of traditional risk factors is routinely challenging.– Besides all the innovative and straightforward biomarker research published in the last decades, only very few markers of cardiovascular risk have shown clinical significance., Among many of them, cystatin C has emerged some years ago as a candidate for improving cardiovascular risk stratification. In the Cardiovascular Health Study (CHS), a […]